Therefore, in this study, we performed a Kaplan–Meier analysis to investigate the role of three different values of ki67 in estimating breast cancer-related invasive disease event-free survival (IDEFS) for patients under 50 years old and over 50 years old, with the aim of enabling clinicians to design personalized therapeutic options according to patients’ age. Here, MKI67 is linked to breast carcinoma.